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Background: Calciphylaxis is a rare but devastating condition in end-stage renal disease 
(ESRD) patients. Most research in the field of calciphylaxis is focused on hemodialysis (HD) 
patients; however, data on calciphylaxis incidence, risk factors, and mortality in peritoneal 
dialysis (PD) patients are limited.  
Methods: In this cohort study, we examined data from adult patients who initiated PD for 
ESRD management at our institute’s PD unit from January 2001 to December 2015. Associations 
with the development of calciphylaxis were examined for clinical, laboratory, and medication 
exposures. Incidence of calciphylaxis and mortality in PD patients who developed calciphylaxis 
were analyzed. Treatments administered to treat calciphylaxis in PD patients were summarized. 
Results: In this cohort of 63 patients, 7 patients developed calciphylaxis (incidence rate: 9.0 per 
1,000 patient-years). Median age of PD patients who developed calciphylaxis was 50 years, 
57% were white, 71% females, and 71% were previously on HD. Female sex, obesity, HD as 
a prior dialysis modality, recurrent hypotension, elevated time-averaged serum phosphorous 
levels, reduced time-averaged serum albumin levels, and warfarin therapy were associated 
with increased calciphylaxis risk in univariate logistic regression analyses. Intravenous sodium 
thiosulfate was administered in 57% of PD patients who developed calciphylaxis. One-year 
mortality in PD patients who developed calciphylaxis was 71% despite multimodal treatment 
including sodium thiosulfate, hyperbaric oxygen, cinacalcet, and wound debridement. 
Conclusion: Calciphylaxis is a rare but frequently fatal condition in PD patients. Our study 
provides critical early insights into calciphylaxis incidence, risk factors, and prognosis in PD 
patients. Sample size and characteristics of patients included in our study limit generalizability 
to overall PD population and warrant examination in larger independent studies. 
Keywords: calcific uremic arteriolopathy, dialysis, hypotension, warfarin
Introduction
Calciphylaxis also known as calcific uremic arteriolopathy is a highly fatal condition 
characterized by dermal arteriolar calcification and thrombosis.1 Calciphylaxis is 
predominantly seen in patients with end-stage renal disease (ESRD) and it remains 
an enigmatic disorder with obscure pathogenesis.2 
Recent reports describing epidemiology, clinical characteristics, and treatments for 
calciphylaxis have focused largely on hemodialysis (HD) patients. These data suggest 
that the incidence of calciphylaxis in HD patients is approximately 3.5 cases per 1,000 
patient-years and it may be on the rise.3,4 Diabetes mellitus, obesity, abnormalities 
in mineral bone parameters, and warfarin therapy have been described as calciphy-
laxis risk factors for HD patients.3,5–7 Cinacalcet has been reported to reduce the risk 
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of  calciphylaxis in HD patients and intravenous sodium 
 thiosulfate has been described to be associated with clinical 
improvement of calciphylaxis in HD patients.8–11 However, 
corresponding data regarding epidemiology, clinical charac-
teristics, and treatments for calciphylaxis in peritoneal dialysis 
(PD) patients are limited despite an earlier  suggestion that PD 
patients may be at a higher risk for calciphylaxis compared to 
HD patients.12,13 Understanding the risk factors and outcomes 
of calciphylaxis in PD patients is critical to the development 
of future interventions to prevent and treat calciphylaxis, espe-
cially as the reasons for an  apparent increase in calciphylaxis 
risk in PD patients are unclear. Therefore, we undertook the 
present cohort study to describe calciphylaxis incidence, risk 
factors, therapies, and mortality in PD patients at our center. 
Methods 
Partners Human Research Committee approved this study, 
the need for patient consent was waived for this minimal 
risk retrospective study. We retrospectively evaluated medi-
cal records of all adult (age >18 years) patients who initiated 
PD for ESRD management at our institute’s PD unit during 
the study period from January 1, 2001 to December 31, 2015. 
Patients who developed calciphylaxis were identified by 
applying a previously published algorithm that incorporates 
natural language processing and by manual chart review.4 
Diagnosis of calciphylaxis was clinically suspected and had 
histopathological confirmation in all patients. Data regarding 
demographics, vital signs, comorbidities, dialysis and ESRD-
related characteristics, medications and mineral bone param-
eters, and nutritional parameters were abstracted from the 
medical record. Laboratory data were time-averaged for each 
patient as follows: for patients who developed calciphylaxis, 
laboratory data were time-averaged from the PD initiation to 
the diagnosis of calciphylaxis and for patients who did not 
develop calciphylaxis, laboratory data were time-averaged 
from the PD initiation to the last available laboratory data. 
Serum calcium levels were corrected for albumin.14 Data for 
warfarin and medications administered to manage mineral 
bone abnormalities were abstracted from the time of PD initia-
tion. In addition for PD patients who developed calciphylaxis, 
ESRD vintage (time between onset of ESRD and development 
of calciphylaxis) and PD vintage (time between start of PD 
and development of calciphylaxis) were computed and data 
regarding calciphylaxis lesions, treatments administered to 
treat calciphylaxis, and one-year mortality were summarized. 
A single investigator conducted data abstractions and another 
investigator independently confirmed data accuracy. 
Median with interquartile range (IQR) and frequency 
percentages were reported for continuous and categorical 
variables, respectively. We calculated calciphylaxis inci-
dence rate per 1,000 patient-years by assuming it follows a 
Poisson distribution and applying the following equation: 
calciphylaxis incidence = (number of new calciphylaxis 
cases) ÷ (sum of person-follow-up time at risk). Categorical 
variables were compared between patients with and without 
calciphylaxis using a Fisher’s exact test and continuous 
variables were compared using a Mann–Whitney U test. 
Univariate logistic regression models were applied to com-
pute odds ratio (OR) and 95% confidence intervals (CI) to 
test the association between risk factors and calciphylaxis 
development. 
Analyses were performed using SAS, version 9.4. Statisti-
cal significance was set at P<0.05.
Results
Incidence and characteristics of PD 
patients who developed calciphylaxis
Our cohort comprised of 63 adult PD patients. During the 
study period, we identified seven patients who developed 
calciphylaxis tendering calciphylaxis incidence of 9.0 per 
1,000 patient-years in PD patients. 
Characteristics of individual PD patients who devel-
oped calciphylaxis are tabulated in Table 1. Median age 
was 50 years (IQR: 34–59), 57% were white, 71% females, 
and 43% had diabetes mellitus. Median body mass index 
was 31.3 kg/m2 (IQR: 23.7–32.8), median ESRD vintage 
was 5.2 years (IQR: 4.1–14.3), and median PD vintage was 
4.1 years (IQR: 3.2–7.0). Most patients (71%) were previ-
ously on HD and were transitioned to PD for access failure 
or for inability to tolerate HD. Recurrent episodes of severe 
hypotension (systolic blood pressure <80 mmHg) preceding 
calciphylaxis were recorded in 43% and 67% of patients 
who had recurrent severe hypotension were previously on 
HD. None of the PD patients who developed calciphylaxis 
were on automated PD and all of them were on 2.5 mEq/L 
calcium dialysate. Although no patient had residual urine 
output at the time of calciphylaxis diagnosis, 86% had weekly 
Kt/Vurea at the recommended goal of ≥1.70.15 Median levels 
of time-averaged mineral metabolism parameters were as fol-
lows – albumin-corrected serum calcium: 9.8 mg/dL (IQR: 
7.9–10.8), phosphorous: 6.1 mg/dL (IQR: 4.8–6.9), and intact 
parathyroid hormone: 270 pg/mL (IQR: 213–657). Median 
levels of time-averaged nutritional parameters were as fol-
lows – serum albumin: 3.1 g/dL (IQR: 2.6–3.2) and normal-
ized protein catabolic rate: 0.78 g/kg/day (IQR: 0.67–0.83). 
At the time of PD initiation, 71% of PD patients who subse-
quently developed calciphylaxis were on warfarin, 86% on 
active vitamin D, 29% on calcium-based phosphate binder, 
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Table 1 Characteristics of PD patients who developed calciphylaxis
Characteristic Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Patient #6 Patient #7
Age, years 50 41 34 59 65 57 30
Sex Female Female Male Female Female Male Female
Race White Black White Black White Black White
Etiology of ESRD Oligonephronia Lupus Lupus Unknown Diabetes Diabetes Primary FSGS
Diabetes mellitus Yes No No No Yes Yes No
Body mass index, kg/m2 27.0 31.3 20.0 32.0 32.9 23.7 32.8
Recurrent severe hypotension 
(SBP<80 mmHg)
Yes No No Yes Yes No No
ESRD vintage, years 32.0 14.3 4.1 5.2 4.8 5.3 3.2
Prior HD therapy Yes Yes Yes Yes No Yes No
PD vintage, years 8.0 7.0 3.4 4.1 4.8 2.1 3.2
Weekly Kt/Vurea 1.98 2.12 1.61 1.99 2.06 2.02 2.71
Serum calcium, mg/dL¶ 9.8 9.3 7.0 10.8 10.3 10.9 7.9
Serum phosphorous, mg/dL  6.3 5.7 6.9 4.8 7.2 6.1 3.6
Serum intact PTH, pg/mL 213 657 89 234 270 678 543
Serum albumin, g/dL 2.2 2.8 3.2 4.1 3.1 2.6 3.2
Normalized protein catabolic rate, g/kg/day 0.81 0.67 0.83 0.67 0.87 0.78 0.75
Warfarin therapy Yes Yes No Yes No Yes Yes
Active vitamin D agent therapy Yes Yes Yes Yes No Yes Yes
Calcium-based phosphate binder therapy No No Yes No No No Yes
Cinacalcet therapy No Yes No No No Yes No
Location(s) of calciphylaxis lesion(s) Bilateral toes Calf, foot Shin Thigh Thigh, 
abdomen
Penis Bilateral thighs, 
forearms
Vital status 1 year after calciphylaxis 
diagnosis
Dead Alive Dead Dead Dead Dead Alive
Note: ¶Serum calcium levels are corrected for serum albumin levels.
Abbreviations: ESRD, end-stage renal disease, FSGS, focal segmental glomerulosclerosis; HD, hemodialysis; PD, peritoneal dialysis; PTH, parathyroid hormone; SBP, systolic 
blood pressure.
and 29% were on cinacalcet. The indications for warfarin 
therapy for PD patients who developed calciphylaxis included 
atrial fibrillation (n=3, 60%) and venous thromboembolic dis-
ease from antiphospholipid antibody syndrome (n=2, 40%). 
The number of calciphylaxis skin lesion(s) for each 
patient ranged from 1 to 6. Lesions exhibited both proximal 
and distal distributions but none involved the site of PD cath-
eter insertion. At the time of calciphylaxis diagnosis, all skin 
lesions were ulcerated and had a black eschar characteristic 
of calciphylaxis as illustrated in Figure 1.
Risk factors for calciphylaxis in PD 
patients
As summarized in Table 2, PD patients who developed 
calciphylaxis were more likely to be female (71% vs 30%, 
P=0.032) and had higher frequencies of obesity (57% vs 
20%, P=0.031), prior history of being on HD (71% vs 30%, 
P=0.032), prior episodes of recurrent hypotension (43% 
vs 7%, P=0.004), and warfarin therapy exposure (71% vs 
16%, P=0.001). Review of echocardiographic data from 
calciphylaxis PD patients with recurrent episodes of hypo-
tension showed that all of these patients had symmetric left 
ventricular hypertrophy and reduced left ventricular ejec-
tion fraction (range: 20–32%). Calciphylaxis patients had 
Figure 1 A representative image showing an ulcerated calciphylaxis lesion with 
black eschar in a peritoneal dialysis patient.
higher time-averaged serum phosphorous levels and lower 
time-averaged serum albumin levels. Other characteristics 
were comparable between PD patients with and without 
calciphylaxis development. 
Results of the univariate logistic regression analyses 
which focused on covariates with statistically significant dif-
ferences between PD patients with and without calciphylaxis 
development are listed in Table 3. Among all the covariates 
with statistically significant association with calciphylaxis 
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risk, warfarin therapy was associated with the highest risk 
for calciphylaxis (OR: 13.06, 95% CI: 2.18–78.05). 
Calciphylaxis treatments and mortality in 
PD patients
All PD patients who developed calciphylaxis underwent 
dressing changes and chemical debridement, and received 
opiate analgesics and nutrition consultations as shown in 
Figure 2. Surgical debridement was conducted in 43%, 57% 
received hyperbaric oxygen, and 43% were transitioned to 
HD. Intravenous sodium thiosulfate was administered in 57% 
patients including in patients who did not transition from PD 
to HD; none received intraperitoneal or intralesional sodium 
thiosulfate. Intravenous sodium thiosulfate was administered 
in our PD unit either through peripheral or central venous 
access. All patients who received intravenous sodium 
 thiosulfate received it as 25 g (mixed in 100 mL of normal 
saline to be infused over 2 hours) 3 times a week. Median 
duration of intravenous sodium thiosulfate treatment was 3.0 
months (IQR: 2.8–5.1). Among the four patients who were 
treated with intravenous sodium thiosulfate, one reported 
nausea and vomiting. There were no other side effects 
recorded from intravenous sodium thiosulfate use. Serum 
bicarbonate levels in four patients who received intravenous 
sodium thiosulfate were reduced by an average of 3.5 mEq/L 
during intravenous sodium thiosulfate therapy.
One-year mortality in PD patients who developed calci-
phylaxis was 71%; all deaths were due to sepsis. One-year 
mortality rate was 67% in patients who underwent surgi-
cal debridement, 50% in patients who received hyperbaric 
oxygen, 75% in patients treated with intravenous sodium 
thiosulfate, and 100% in patients who transitioned from 
PD to HD.
Discussion 
Despite first descriptions of calciphylaxis over 5 decades ago, 
little is known regarding its epidemiology and risk factors in 
PD patients.1,13,16,17 Our study was designed to address this 
knowledge gap. In our single center cohort of 63 PD patients, 
7 patients developed calciphylaxis during the 15-year study 
follow-up period. We noted a number of potential risk fac-
tors for calciphylaxis in PD patients. One-year mortality in 
PD patients who developed calciphylaxis was 71% despite 
multimodal treatment. 
Table 2 Comparison of characteristics between PD patients who developed calciphylaxis and PD patients who did not develop 
calciphylaxis 
Characteristic Calciphylaxis
(n=7)
No calciphylaxis
(n=56)
P-value
Age, years 50 (IQR: 34–59) 54 (IQR: 39–70) 0.941
Female sex,% 71 30 0.032
White race, % 57 63 0.621
Diabetes mellitus, % 43 41 0.881
Obesity, % 57 20 0.031
Recurrent severe hypotension, % 43 7 0.004
Prior HD therapy, % 71 30 0.032
Weekly Kt/Vurea 2.02 (IQR: 1.98–2.12) 2.10 (IQR: 1.89–2.35) 0.781
Serum calcium, mg/dL¶        9.8 (IQR: 7.9–10.8) 9.0 (IQR: 8.5–10.1) 0.563
Serum phosphorous, mg/dL 6.1 (IQR: 4.8–6.9) 3.2 (IQR: 2.2–3.9) 0.023
Serum intact PTH, pg/mL 270 (IQR: 213–657) 291 (IQR: 182–452) 0.601
Serum albumin, g/dL 3.1 (IQR: 2.6–3.2) 3.7 (IQR: 3.6–4.6) 0.049
Normalized protein catabolic rate, g/kg/day 0.78 (IQR: 0.67–0.83) 1.01 (IQR: 0.80–1.06) 0.092
Warfarin therapy, % 71 16 0.001
Active vitamin D agent therapy, % 86 49 0.821
Calcium-based phosphate binder therapy, % 29 33 0.512
Cinacalcet therapy, % 29 30 0.672
Note: ¶Serum calcium levels are corrected for serum albumin levels.
Abbreviations: HD, hemodialysis; IQR, interquartile range; PD, peritoneal dialysis; PTH, parathyroid hormone.
Table 3 Results from univariate logistic regression analyses 
showing risk associations with statistical significance for calciphyl­
axis development in PD patients
Covariate OR 95% CI
Female sex 5.74 1.01–32.54
Obesity 5.45 1.06–27.99
Recurrent severe hypotension 9.75 1.60–59.56
Prior HD therapy 5.74 1.01–32.54
Serum phosphorous (per 1 mg/dL increase) 2.13 1.01–4.56
Serum albumin (per 1 g/dL reduction) 2.21 1.02–3.65
Warfarin therapy 13.06 2.18–78.05
Abbreviations: CI, confidence intervals; HD, hemodialysis; PD, peritoneal dialysis; 
OR, odds ratio.
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Calciphylaxis incidence rate of 9.0 per 1,000 patient-
years in our PD cohort is higher than the recently reported 
calciphylaxis incidence in HD patients of 3.5 cases per 1,000 
patient-years.4,9,18 Considering the sample size limitation of 
our study and single center experience, definitive conclu-
sions regarding comparative effectiveness of PD vs HD for 
calciphylaxis risk cannot be made; however, our study adds to 
the debate in the literature regarding whether PD as a dialysis 
modality confers a higher calciphylaxis risk than HD.12,13,19 It 
is important to note that although PD was the dialysis modal-
ity for our study patients when calciphylaxis was diagnosed, 
many patients were previously on HD and required transi-
tion to PD for access failure or recurrent hypotension. In 
that regard, these were likely “the sickest of the sick” ESRD 
patients and our findings may not be generalizable to the 
overall PD population. Change in dialysis modality per se has 
been described to be associated with worse outcomes such 
as mortality.20 Furthermore, prevalence of well-described 
calciphylaxis risk factors such as warfarin therapy and obe-
sity was higher in PD patients who developed calciphylaxis 
compared to previously published prevalence of these risk 
factors in HD patients who developed calciphylaxis.3,5–7,18 
Thus, it is possible that it is these risk factors and not dialysis 
modality that dictates calciphylaxis risk. Previous studies 
have shown that PD is associated with more abnormalities in 
phosphorous and albumin than HD, especially once residual 
renal function has deteriorated.21,22 Thus, it is possible that 
our data suggest that those PD patients who have difficulty 
controlling phosphorus or maintaining their albumin may be 
at increased risk of calciphylaxis. 
The potential risk associations observed in our study 
may be instructive to understand calciphylaxis pathobiology. 
Warfarin (vitamin K antagonist) as a potential risk factor 
suggests a critical role of vitamin K-dependent proteins 
such as MGP in the inhibition of vascular calcification.23 
Recurrent episodes of hypotension preceding calciphylaxis 
development may point toward reduced perfusion serving as 
a trigger for ischemia in dermal beds with calcified arterioles. 
Low normalized protein catabolic rate and serum albumin 
in PD patients who developed calciphylaxis may implicate 
that the malnutrition–inflammation complex is at play.24,25 
It is likely that in our study, a statistically significant 
difference between PD patients with and without calci-
phylaxis was not noted due to limited sample size and 
one-time assessment (at PD initiation) of certain covariates 
such as medications. This is particularly important as the 
pathogenesis of calciphylaxis is likely multifactorial, as 
supported by larger studies3,6 in the HD population that 
noted multiple calciphylaxis risk factors, including diabetes 
mellitus and advanced age. Small sample size also limited 
us from conducting multivariable adjusted analyses to exam-
ine whether associations observed in univariate analyses 
Medical wound management
Debridement
Hyperbaric oxygen
Pain management
Intravenous sodium thiosulfate
Intensification of PD prescription
Patient #1
Patient #2
Patient #3
Patient #4
Patient #5
Patient #6
Patient #7
Transition to HD
Nutrition consult
Avoidance of warfarin
Surgical parathyroidectomy
Lowering calcium intake
Avoidance of active vitamin D
Cinacalcet
Figure 2 Components of multimodal treatment administered to PD patients who developed calciphylaxis.
Abbreviations: PD, peritoneal dialysis; HD, hemodialysis.
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remain  consistent when adjusted for other covariates. Larger 
studies are needed to ascertain calciphylaxis risk in PD vs 
HD patients and to confirm risk associations observed in 
our study. These future studies should be multicenter to 
improve generalizability, should include assessments of 
novel dynamics such as recurrent hypotension, echocar-
diographic parameters, and PD technique (eg, automated 
PD vs continuous ambulatory PD), and should investigate 
longitudinal effects of residual kidney function and medi-
cations. Given the mortality associated with calciphylaxis, 
identifying patient and modality characteristics that may 
confer increased risk is important when helping patients 
choose a dialysis modality.
In our study, PD patients who developed calciphylaxis 
received multimodal treatment.  Although successful 
calciphylaxis improvement has been reported with such 
 multimodal treatment, our patients had a high mortality 
rate.26–28 This could be reflective of high mortality due 
to ulcerated calciphylaxis lesions and/or the overall poor 
prognosis in patients with recurrent hypotension. Alterna-
tive methods of sodium thiosulfate administration were not 
applied in our study patients, considering the potential risk 
of further ulceration (with intralesional) and concern for 
chemical peritonitis (with intraperitoneal).29–32 
In conclusion, calciphylaxis is a rare but fatal complica-
tion in PD patients. Our study provides insights into calci-
phylaxis epidemiology and risk factors in PD patients and 
motivates future investigation.  
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